Teva Pharmaceutical Industries Limited (NYSE:TEVA) Director Sells $6,294,860.00 in Stock

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Teva Pharmaceutical Industries Trading Up 0.9 %

Shares of Teva Pharmaceutical Industries stock traded up $0.20 during trading on Thursday, reaching $22.62. The company’s stock had a trading volume of 5,528,470 shares, compared to its average volume of 9,410,053. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a 52-week low of $10.39 and a 52-week high of $22.80. The firm’s 50-day moving average is $18.06 and its two-hundred day moving average is $17.64. The company has a market cap of $25.63 billion, a price-to-earnings ratio of -26.61, a PEG ratio of 0.99 and a beta of 0.79.

Analyst Ratings Changes

Several research analysts have recently weighed in on TEVA shares. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. UBS Group raised their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average target price of $20.88.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently added to or reduced their stakes in TEVA. DGS Capital Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 6.8% in the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after purchasing an additional 872 shares during the last quarter. Franklin Resources Inc. grew its holdings in Teva Pharmaceutical Industries by 141.7% in the 3rd quarter. Franklin Resources Inc. now owns 155,091 shares of the company’s stock worth $2,674,000 after acquiring an additional 90,920 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Sanctuary Advisors LLC increased its position in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after acquiring an additional 664 shares during the period. Finally, TCW Group Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth about $1,286,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.